Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMahesh SwaminathanÁBÁlex BatallerKTKoichi Takahashi

Discussion

Loading...

Member takes

Overview

Phase II trial shows high rates of U-MRD remission in chronic lymphocytic leukemia using BTK inhibitors and venetoclax.

Key Points

  • 88% achieved undetectable MRD in blood after 12-months treatment with combined therapy.
  • Next-generation sequencing assessed MRD in bone marrow and blood at the end of treatment cycles.
  • Phase II trial evaluated pirtobrutinib, venetoclax, and obinutuzumab's efficacy and safety in CLL.
  • No patients developed disease recurrence after discontinuing therapy at follow-up.

Cite This Study

Swaminathan et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d74ehttps://doi.org/10.1182/blood-2025-680
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial2025
  2. 2Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG).2025
  3. 3Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study2025 · 1 citations
  4. 4Zanubrutinib + obinutuzumab + sonrotoclax in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL): Initial results from an ongoing phase 1/1b study, BGB-11417-1012025 · 1 citations
  5. 5Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor2025 · 2 citations